Tirzepatide in Miami: Am I a Good Candidate? A Provider's Guide to Zepbound
Tirzepatide (Zepbound/Mounjaro) is delivering stronger weight loss results than semaglutide in clinical trials. But is it right for you? This provider's guide covers candidacy criteria, what the first 90 days look like, and how to get started at SkinUp in Kendall, Miami.
Tirzepatide in Miami: Am I a Good Candidate? A Provider’s Guide to Zepbound
If you’ve been researching weight loss options in Miami, you’ve likely come across tirzepatide — the active ingredient in Zepbound and Mounjaro. And you’ve probably heard that it outperforms semaglutide. The clinical data backs that up. The SURMOUNT-5 head-to-head trial showed tirzepatide produced an average of 20.2% body weight loss over 72 weeks, compared to 13.7% for semaglutide.
That’s a meaningful difference. It’s why many patients walk into consultations at SkinUp in Kendall asking specifically about tirzepatide rather than GLP-1 therapy in general.
But “tirzepatide works better on average” doesn’t automatically make it the right starting point for everyone. Candidacy, health history, and individual response all matter. This guide covers what you actually need to know before deciding.
What Makes Tirzepatide Different
Semaglutide activates GLP-1 receptors — the brain pathway that signals fullness and slows gastric emptying. Tirzepatide does that, plus one more: it’s a dual GIP/GLP-1 receptor agonist, activating a second hormonal pathway that amplifies appetite suppression and supports metabolic efficiency.
In practice, the dual mechanism tends to translate into faster appetite reduction, more consistent weight loss, and — in the clinical data — a higher proportion of patients achieving 15%+ body weight loss.
This isn’t a minor distinction. It’s one reason tirzepatide has become the leading choice for many patients and providers in the medical weight loss space. But mechanism alone doesn’t determine appropriateness. That’s where candidacy comes in.
For a deeper look at how both medications work, see our full guide: Semaglutide & Tirzepatide for Weight Loss in Miami.
Who Is a Good Candidate for Tirzepatide (Zepbound)?
Tirzepatide (Zepbound) is FDA-approved for chronic weight management in adults who meet one of the following:
- BMI ≥ 30 (classified as obesity)
- BMI ≥ 27 (overweight) with at least one weight-related health condition, such as:
- High blood pressure (hypertension)
- Type 2 diabetes or prediabetes
- High cholesterol or triglycerides (dyslipidemia)
- Obstructive sleep apnea
- Cardiovascular disease
Important safety note: Even if you meet the BMI criteria above, tirzepatide is contraindicated for certain patients. You should not use Zepbound if you have a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2), or if you have had a serious allergic reaction to tirzepatide. Tirzepatide is not recommended during pregnancy. Patients with a history of pancreatitis or severe gastrointestinal disease require careful evaluation before starting. Your SkinUp provider will review your complete medical history to confirm whether tirzepatide is appropriate for your situation.
Beyond those criteria, patients who tend to be particularly strong candidates for tirzepatide specifically include:
Patients with significant weight loss goals. If you’re looking to lose 15% or more of your body weight, the clinical data consistently shows tirzepatide outperforms semaglutide at that threshold. For patients with a substantial amount of weight to address, tirzepatide’s dual mechanism provides a meaningful clinical advantage.
Patients with type 2 diabetes. Tirzepatide (as Mounjaro) was originally developed for type 2 diabetes management and has strong evidence in this population. If you have T2D alongside weight-related concerns, tirzepatide addresses both simultaneously.
Patients who have tried semaglutide with limited results. It is not uncommon to see initial progress on semaglutide that plateaus before reaching your goal. For patients in this situation, transitioning to tirzepatide often restores progress.
Patients who want the strongest available option from the start. If you are committed to a medically supervised program and want to maximize your opportunity for substantial weight loss, tirzepatide’s clinical profile makes a compelling case.
Candidacy is ultimately determined by your provider after a full evaluation — not by a checklist. At SkinUp, every weight management program begins with a comprehensive consultation that includes your health history, body composition analysis, and an honest conversation about which approach is most appropriate for you.
When Semaglutide Might Be the Better Starting Point
Tirzepatide is not the right answer for everyone, and a good provider will tell you that directly.
GI-sensitive patients. Tirzepatide’s dual action can produce stronger gastrointestinal effects — especially during early titration. Patients with a history of significant GI sensitivity may tolerate semaglutide’s more gradual onset better as a starting point.
Patients new to GLP-1 therapy who prefer a conservative start. Semaglutide is well-studied with a decade-plus of safety data. For patients who prefer a more measured introduction to this class of medications, starting with semaglutide is a reasonable and clinically appropriate path.
Cost considerations. Depending on your insurance situation and which manufacturer-direct programs apply to you, one option may be more accessible. Our GLP-1 pricing guide covers both in detail, including Novo Nordisk’s NovoCare programs and Lilly’s LillyDirect options.
What the First 90 Days of Tirzepatide Look Like
Understanding the titration process helps set realistic expectations and reduces anxiety about side effects.
Weeks 1–4: Starting Dose (2.5 mg Weekly)
Tirzepatide begins at 2.5 mg weekly. At this dose, many patients notice early appetite changes within the first 1–2 weeks — food feels less compelling, portions naturally decrease. Some experience mild nausea, particularly in the early days. Most find it manageable.
Practical tips for this phase: eat smaller, more frequent meals; prioritize protein to protect muscle mass; stay well hydrated; and avoid heavy or greasy meals, especially in the first two weeks.
Weeks 4–8: First Dose Increase (5 mg Weekly)
After four weeks at the starting dose, most patients advance to 5 mg weekly. Appetite suppression typically intensifies, and early, measurable weight changes are often noticeable by the end of this phase — clothes fitting differently, the scale moving consistently.
Some patients experience a brief return of mild GI symptoms at the new dose; this usually settles within one to two weeks.
Months 3–6: Finding Your Therapeutic Dose
Doses continue to increase in 2.5 mg steps every four weeks as tolerated — to 7.5 mg, 10 mg, and up to a maximum of 15 mg weekly. By month three, most patients are at a dose where weight loss is consistent and appetite suppression is well-established.
Regular check-ins with your provider during this phase are essential. Your response, tolerance, and progress all inform how your program should evolve.
Tirzepatide vs. Semaglutide: Quick Comparison
| Tirzepatide (Zepbound) | Semaglutide (Wegovy) | |
|---|---|---|
| Mechanism | Dual GIP + GLP-1 | GLP-1 only |
| Avg. weight loss (clinical) | ~20% body weight | ~14% body weight |
| Starting dose | 2.5 mg weekly | 0.25 mg weekly |
| GI effects | Moderate to stronger | Moderate |
| Self-pay starting price | From ~$299/month (LillyDirect) | From ~$349/month (NovoCare) |
| FDA approval for weight loss | Zepbound (Nov. 2023) | Wegovy (June 2021) |
Getting Started at SkinUp in Kendall, Miami
SkinUp Aesthetics & Wellness offers a provider-guided weight management program that may include tirzepatide or semaglutide when clinically appropriate, for patients throughout Kendall, Coral Gables, South Miami, and the surrounding communities.
Our program includes:
- Comprehensive initial evaluation — health history review, body composition analysis, and a candid conversation about your goals and what approach is appropriate for your situation
- Personalized medication plan — your starting dose, titration schedule, and ongoing adjustments based on your individual response
- Nutritional guidance — how to structure your meals, what to prioritize, and how to protect muscle mass as you lose weight
- Regular monitoring and follow-up — check-ins to assess progress, manage side effects, and optimize your program over time
- Integration with complementary wellness services — as your body changes, services like IV therapy and vitamin injections can support your progress from the inside out
Cherry financing is available to make your program more accessible. Apply with Cherry in about 60 seconds — no impact to your credit score.
Frequently Asked Questions
What is the difference between Mounjaro and Zepbound?
Both are brand names for tirzepatide — the same active molecule. Mounjaro is FDA-approved for type 2 diabetes management. Zepbound is FDA-approved specifically for chronic weight management. Your provider determines which applies to your clinical situation.
How much does tirzepatide cost in Miami?
Retail pharmacy pricing for Zepbound runs $1,069–$1,284/month without insurance. Lilly’s LillyDirect self-pay program offers single-dose vials starting at $299/month (2.5 mg starting dose) and $449/month for higher maintenance doses. Program fees at SkinUp are reviewed during your consultation. See our full pricing guide for a detailed breakdown of all available access pathways.
Can I switch from semaglutide to tirzepatide?
Yes — and it’s clinically common. Switching requires your provider to evaluate your current progress, tolerance, and goals before establishing the right timing and approach. Many patients who’ve plateaued on semaglutide find that transitioning to tirzepatide restores consistent progress.
Does SkinUp offer tirzepatide in Miami?
Yes. SkinUp’s weight management program may include tirzepatide (Zepbound) when clinically appropriate, as part of a provider-supervised, personalized plan.
What is tirzepatide’s FDA approval for weight loss?
Zepbound received FDA approval in November 2023 for chronic weight management in adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity — including hypertension, type 2 diabetes, dyslipidemia, sleep apnea, or cardiovascular disease.
The Bottom Line
Tirzepatide delivers stronger average weight loss outcomes than any other medication currently available for this indication. For patients in the Miami area who meet the candidacy criteria and are ready for a structured, medically supervised program, it represents a meaningful step forward in what’s achievable.
But the most effective approach is the one designed around you specifically — your health history, your goals, and your individual response. That’s what a thorough evaluation is for.
At SkinUp in Kendall, every weight management conversation starts with a proper assessment and an honest recommendation. If tirzepatide is the right fit, we’ll say so. If a different path makes more sense for your situation, we’ll say that too.
Learn more about our weight management program — or schedule a consultation to discuss your options with no pressure and no defaults.
Sources
- Tirzepatide as Compared with Semaglutide for Treatment of Obesity (SURMOUNT-5) — NEJM / PubMed
- FDA Approves Zepbound (Tirzepatide) for Chronic Weight Management — Eli Lilly Investor Relations
- Lilly Lowers Price of Zepbound Single-Dose Vials for Self-Pay Patients — Eli Lilly Investor Relations
- Zepbound Prescribing Information — FDA.gov
- Zepbound Cost Information — Lilly Pricing Info